List of contributors

Chen, Hongzhen; Chen, Pengyu; El-Hashash, Ahmed; Fan, Shunwu; Fu, Xuekun; Gu, Chenhui; Huang, Yü; Huang, Zhenxiang; Jiang, Deming; Liang, Chao; Lin, Xianfu; Liu, Mengyun; Pan, Kai-Feng; Wu, Haoyu; Xu, Tengjing; Yin, Zi; Yuan, Dailin; Zhang, Yuxiang; Zhou, Guangqian; Zhu, Yu

doi:10.1016/b978-0-323-91938-8.00014-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Doxorubicin Activates Inflammasome -Dependent Andindependent...mentioning

confidence: 99%

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Wang,

Kaur,

et al. 2024

Preprint

View full text Add to dashboard Cite

Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of DAMPs (e.g., cell-free DNA and ATP) and cytokines (e.g., IL-1β and IL-18). Accordingly, doxorubicin activated the AIM2 and NLRP3 inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.

show abstract

Section: Doxorubicin Activates Inflammasome -Dependent Andindependent...mentioning

confidence: 99%

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Wang,

Kaur,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The effects of doxorubicin on macrophages have been reported (Chen et al, 2023, Saleh et al, 2021. To test the hypothesis that these cells were implicated in the inflammatory phenotype of mice treated with doxorubicin, we treated bone marrow-derived macrophages (BMMs) with lipopolysaccharide (LPS) for 3 hours to induce the expression of inflammasome components (Wang et al, 2021 ), then with various concentrations of this drug for 16 hours.…”

Section: Doxorubicin Activates Inflammasome -Dependent Andindependent...mentioning

confidence: 99%

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Wang,

Kaur,

et al. 2024

Preprint

View full text Add to dashboard Cite

Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger-associated molecular patterns (DAMPs; e.g., cell-free DNA and ATP) and cytokines (e.g., IL-1β and IL-18). Accordingly, doxorubicin activated the absent in melanoma (AIM2) and NLR family pyrin domain containing 3 (NLRP3) inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.

show abstract

List of contributors

Cited by 2 publications

References 0 publications

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Contact Info

Product

Resources

About